Acquisition History / ESOF III Investment Fund / Biocon Biologics Limited
ESOF III Investment Fund Acquires Biocon Biologics Limited
Announced January 2023 — Price not disclosed (CCI combination order)
What happened
Biosimilars business of Biocon Acquired through ESOF III Investment Fund, a vehicle of Edelweiss Alternative Asset Advisors Limited. Source: https://www.cci.gov.in/images/summaryorders/en/summary1683633110.pdf
- Acquirer
- ESOF III Investment Fund
- Target
- Biocon Biologics Limited
- Announced
- January 2023
- Price
- Price not disclosed (CCI combination order)
- Industry
- Biopharmaceuticals
- Buyer type
- Private equity
- Fund vehicle
- ESOF III Investment Fund
- Backing investors
- Edelweiss Alternative Asset Advisors Limited
- Status
- Closed
By the numbers
Frequently Asked Questions About This Acquisition
When did ESOF III Investment Fund acquire Biocon Biologics Limited?
ESOF III Investment Fund acquired Biocon Biologics Limited on January 2023. This was ESOF III Investment Fund's 1st publicly tracked acquisition out of 1 we have on record.
How much did ESOF III Investment Fund pay for Biocon Biologics Limited?
ESOF III Investment Fund paid Price not disclosed (CCI combination order) for Biocon Biologics Limited.
What does Biocon Biologics Limited do?
Biosimilars business of Biocon Acquired through ESOF III Investment Fund, a vehicle of Edelweiss Alternative Asset Advisors Limited. Source: https://www.cci.gov.in/images/summaryorders/en/summary1683633110.pdf
What other Biopharmaceuticals companies has ESOF III Investment Fund acquired?
Biocon Biologics Limited is ESOF III Investment Fund's only publicly tracked acquisition in Biopharmaceuticals so far.
More Biopharmaceuticals acquisitions
Servier acquires Muscular dystrophy business of Edgewise Therapeutics Inc.
$2.65B · 2026
Ono Pharmaceutical Co., Ltd. acquires Deciphera Pharmaceuticals, Inc.
$2.40B · 2024
Kotak Special Situations Fund acquires Biocon Biologics Limited
Price not disclosed (CCI combination order) · 2023